# Neptune Medical

> Neptune Medical is a Silicon Valley medical device company building the future of gastrointestinal endoscopy around its proprietary Dynamic Rigidization technology, which lets a thin-walled tube toggle instantly between flexible and rigid states using vacuum. Its first FDA-cleared product, the Pathfinder overtube, tackles the old and unglamorous problem of endoscope 'looping' during colonoscopy, and has been used in more than 15,000 patients. The company is now extending that platform into the Triton robotic endoscopy system, which posted a clean 100% cecal intubation rate with no adverse events in its first-in-human study.

- **Founded:** 2016
- **Headquarters:** Burlingame, California, United States
- **Founders:** Alex Tilson (Founder & CEO)
- **Team size:** ~140 employees
- **Products:** Dynamic Rigidization, Pathfinder Endoscope Overtube, Triton Robotic Endoscopy System
- **Notable:** FDA clearance of Pathfinder, the first commercial device using Dynamic Rigidization technology, Pathfinder used in more than 15,000 patients at leading U.S. hospitals and academic centers, Raised $97M Series D in August 2024 with participation from Olympus and Sonder Capital

## Products & services

- **Dynamic Rigidization** — Proprietary platform technology that uses vacuum to instantly toggle thin-walled tubes - overtubes, catheters, cannulae - between flexible and rigid states, as needed throughout a procedure to manage looping.
- **Pathfinder Endoscope Overtube** — Neptune's first FDA-cleared commercial device. A rigidizing overtube that rides over an endoscope to manage loop formation, aid navigation, and control the scope tip during diagnostic and therapeutic GI procedures including colonoscopy. Used in 15,000+ patients.
- **Triton Robotic Endoscopy System** — A robotic endoscopy platform for colon navigation with precision control, built on Dynamic Rigidization. Investigational - not yet available for sale. Passed a 50-patient first-in-human study with 100% cecal intubation and no adverse events.

## Achievements

- FDA clearance of Pathfinder, the first commercial device using Dynamic Rigidization technology
- Pathfinder used in more than 15,000 patients at leading U.S. hospitals and academic centers
- Raised $97M Series D in August 2024 with participation from Olympus and Sonder Capital
- Triton robotic endoscopy first-in-human (CARE 1) study: 100% cecal intubation, no adverse events across 50 patients
- Triton study reported 54.2% adenoma detection rate, 100% polypectomy success, and 67% lower operator burden vs manual colonoscopy
- Cleanly spun out Jupiter Endovascular to sharpen focus on gastroenterology robotics

## Latest updates

- **2026-05** — Announced positive first-in-human results for the Triton Robotic Endoscopy System (CARE 1 study) at Digestive Disease Week 2026 - 100% cecal intubation, no adverse events, 54.2% ADR.
- **2024-08** — Closed a $97M Series D financing and spun out Jupiter Endovascular as an independent company to focus on GI robotics.

## Links

- Website: https://neptunemedical.com
- LinkedIn: https://www.linkedin.com/company/neptunemedical

---

Profile page: https://yespress.io/neptune-medical
Published by YesPress — https://yespress.io
Last updated: 2026-07-11